All In Biotech

Drug Trial Radar · NCT06468358

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

194

Planned (sponsor's estimate)

Start

Jun 19, 2024

Primary completion

Dec 30, 2026

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Shanghai East Hospital
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody,LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.

Conditions

  • Solid Tumor

Interventions

  • LB1410Drug

    anti-PD-1/TIM3 bispecific antibody

  • LB4330Drug

    anti-claudin18.2/IL-10 fusion protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)Time frame: up to 60 days following last dose
  2. Incidence and severity of serious adverse events (SAEs) and other special interest (immune-related AEs)Time frame: up to 60 days following last dose
  3. Incidence of Dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  4. Maximum tolerance toxicity (MTD) and recommended dose for Phase II (RP2D) definitionTime frame: up to 1 year
  5. Overall response rate (ORR)Time frame: From first participant until last participant assessment, an average of 8 months
  6. Disease control rate (DCR)Time frame: From first participant until last participant assessment, an average of 8 months
  7. Duration of overall Response (DoR) by RECIST version 1.1Time frame: From first participant until last participant assessment, an average of 8 months
  8. Progression Free Survival (PFS) by RECIST version 1.1Time frame: From first participant until last participant assessment, an average of 8 months
  9. DDCTime frame: From first participant until last participant assessment, an average of 8 months
  10. Overall Survival (OS) durationTime frame: From first participant until last participant assessment, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.